Arctic Bioscience - Share Issue/Capital Change 2022

ABS - Exercise of share options and issuance of shares

Ole Arne Eiksund, outgoing CEO of Arctic Bioscience has exercised 76,180 share

options at strike price NOK 9.845.

The Board of Directors will issue the shares, pursuant to authorization granted

by the Company's Annual General Meeting. Following the increase, the Company's

shares outstanding will be 24,375,719 shares.

For further information, please contact:

Danielle Glenn

CFO of Arctic Bioscience AS

Phone: +47 909 98 201

About Arctic Bioscience

Arctic Bioscience is a biotech company developing and commercializing

nutraceutical products based on herring roe oil. Herring roe oil contains lipids

that are essential to maintain cell membranes, contributing to normal

functioning of brain, heart, and vision. Nutraceuticals from Arctic Bioscience

are sold globally as bulk ingredients to other companies making dietary

supplements, and as finished goods under the Romega brand. The strategy is to

switch sales from bulk to finished goods and focus markets are USA and China.

The company is developing HRO350 - a novel investigational drug candidate with

herring roe as raw material. HRO350 is being developed for treatment of mild-to

-moderate psoriasis. This is a large patient group in need of new effective

medicines. Arctic Bioscience is led by a team of highly competent people with

experience in developing marine oils and experience from global pharmaceutical

companies.

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.

AI assistant